Dr Pusztai is Professor of Medicine at Yale University, Director of Breast Cancer Translational Research and Co-Director of the Yale Cancer Center Genomics Genetics and Epigenetics Program. He is also Chair of the Breast Cancer Research Committee of the Southwest Oncology Group (SWOG). Dr Pusztai has made important contributions to establish that estrogen receptor-positive and-negative breast cancers have fundamentally different molecular, clinical and epidemiological characteristics. He has been a pioneer in evaluating gene expression profiling as a diagnostic technology to predict chemotherapy and endocrine therapy sensitivity and have shown that different biological processes are involved in determining the prognosis and treatment response in different breast cancer subtypes. Dr. Pusztai’ s research also clarified the clinical value of preoperative (neoadjuvant) chemotherapy in different breast cancer subtypes. With Komen funds, he studies the immune microenvironment of primary and metastatic breast cancers before and after therapy, and uses that knowledge to design new treatment strategies for breast cancer.